77 results
8-K
EX-99.1
BFRI
Biofrontera Inc
3 May 24
Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants
9:15am
ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed
8-K
EX-99.1
BFRI
Biofrontera Inc
26 Mar 24
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
4:45pm
company requirements; the Company’s ability to regain compliance with Nasdaq continued listing standards, the Company’s ability to retain and hire key
8-K
EX-99.1
BFRI
Biofrontera Inc
15 Mar 24
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
5:20pm
to regain compliance with Nasdaq continued listing standards, the Company’s ability to retain and hire key personnel; the sufficiency of cash resources
8-K
EX-99.1
BFRI
Biofrontera Inc
23 Feb 24
Biofrontera Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules
9:26am
ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed
8-K
EX-99.1
33en uysd
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
8-K
EX-99.2
ykw038zc118frhngon63
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
8-K
EX-99.1
omme 8fe3a
5 Feb 24
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz® to Permit Up to Three Tubes per Use
5:25pm
8-K
EX-99.1
fbzq jhvgv2w
11 Jan 24
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023
4:40pm
8-K
EX-99.1
1dq2d09jpl3v
9 Nov 23
Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
5:15pm
8-K
EX-99.1
glterv wkmvg0
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
424B4
skaq4cpw0g
1 Nov 23
Prospectus supplement with pricing info
5:09pm
8-K
EX-99.1
pjb0bds d9bfoxy8
10 Oct 23
Patent Application Filed with Potential to Extend Ameluz® Protection to 2043
9:15am
8-K
EX-99.1
ohvjrw1ujxqpooy
4 Oct 23
Biofrontera Inc. Announces Preliminary Third Quarter Revenues
8:45am
8-K
EX-99.1
ry6zr9kfoln5otjh
11 Aug 23
Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update
7:30am